Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hand transplant protocol aims to cut lifelong drug risks

NCT ID NCT01459107

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This Phase 2 trial at Johns Hopkins University will transplant donated hands onto 30 people who have lost one or both hands or arms. The key innovation is a bone marrow cell therapy designed to allow the body to accept the new hand with just one low-dose anti-rejection drug, instead of the usual three-drug cocktail. The goal is to restore function and appearance while reducing the long-term risks of infection, cancer, and other side effects from standard immunosuppression.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
deceased donor hand transplantation combined with bone marrow cell therapy and single-drug immunosuppression
What this could lead to
If successful, this could make hand transplants safer and more widely available by reducing the need for strong, lifelong anti-rejection drugs.
What could go wrong
This is an early Phase 2 trial with only 30 participants. The new immunosuppression approach may still cause rejection, infection, or other side effects, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2011

Expected to finish

Jun 2036

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 69 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Recipient Inclusion Criteria: * Recent (≥6 months) or remote (i.e., several decades) unilateral or bilateral upper limb loss (below the shoulder) desiring limb transplantation. * Below-shoulder amputation. * Functionless or minimally functional hand desiring removal of functionless / minimally functional hand followed by transplantation. * Male or female and of any race, color or ethnicity. * Aged 18-69 years. * Completes the protocol informed consent form. * No co-existing medical condition which, in the opinion of the study team, could affect the immunomodulatory protocol, surgical procedure, or functional results (see Donor and Recipient Exclusion Criteria below. If the condition is amenable to treatment, the study team must agree that said condition should not significantly enhance the surgical risks of upper extremity transplantation.) * No co-existing psycho-social problems (i.e., alcoholism, drug abuse). * Negative for malignancy for past 5 years. * Negative for HIV at transplant. * Negative crossmatch with donor. * If female of child-bearing potential, negative serum pregnancy test. * If female of child-bearing potential, consent to use reliable contraception for at least one year following transplantation. * Consents to bone marrow infusion as part of the treatment regime. * USA citizen or equivalent, or foreigner with documentation of ability to pay for transplant and required follow-up care. * Patient agrees to comply with the protocol and states a dedication to the immunomodulatory treatment regime. Donor Inclusion Criteria: Donors will be selected by the upper extremity transplant team in conjunction with the organ procurement organization (OPO) according to the following criteria: * Brain dead meeting the criteria for Determination of Death. * Family consent for limb donation. * Stable donor (i.e., does not require excessive vasopressors to maintain blood pressure). * Aged 16 - 65 years. * Limb matched for size with recipient. * Same blood type as recipient. * Negative lymphocytotoxic crossmatch. * Accurately matched for gender, skin tone, and race (relative requirements depending on recipient consent). Exclusion Criteria: • Positive for any of the following conditions: * Untreated sepsis. * HIV (active or seropositive). * Active tuberculosis. * Hepatitis B or C. * Viral encephalitis. * Toxoplasmosis. * Malignancy (within past 5 years). * Current/recent (within 3 months of donation/screening consent) IV drug abuse. * Paralysis of ischemic or traumatic origin. * Inherited peripheral neuropathy. * Infectious, post infectious, or inflammatory (axonal or demyelinating) neuropathy. * Toxic neuropathy (i.e. heavy metal poisoning, drug toxicity, industrial agent exposure). * Mixed connective tissue disease. * Severe deforming rheumatoid or osteoarthritis in the limb. Donor Only: • Tattoos: * Non-professional tattoo within last 6 months, or * Personally identifiable tattoo (i.e., donor name) on potential transplant. Recipient Only: * Type I (insulin-dependent) diabetes mellitus * Conditions that, in the opinion of the study team, may impact the immunomodulatory protocol potentially exposing the recipient to an unacceptable risk under immunosuppressive treatment. * Sensitized recipients with high levels (50%) of panel-reactive human leukocyte antigen (HLA) antibodies. * Conditions that may impact the success of the surgical procedure or increase the risk of postoperative complications including inherited coagulopathies like Hemophilia, Von-Willebrand's disease, Protein C and S deficiency, Thrombocythemias, Thalassemias, Sickle Cell disease, etc. * Mixed connective tissue diseases and collagen diseases can result in poor wound healing after surgery. * Conditions that may impact functional outcomes including Lipopolysaccharidosis and amyloidosis (may impact nerve regeneration) or rare disorders of bone healing like osteopetrosis. * Patients considered unsuitable per the consulted Psychiatrists appraisal.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Amputation, traumatic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Amputation, Traumatic Hand Injuries injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Johns Hopkins University School of Medicine

    RECRUITING

    Baltimore, Maryland, 21287, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.